Oncotelic Therapeutics, Inc. announced that Fatih Uckun, MD, Ph. D, Chief Medical Officer (“CMO”) of Oncotelic Therapeutics, Inc. (the “Company”), notified the Company of his resignation as the Company's CMO, effective February 28, 2023. Dr. Seymour Fein MD, Chief Regulatory Officer (“CRO”) of the Company, will be taking over the CMO role.